Rheumatology
Schulert Lab

Schulert Research Lab

The primary focus of the Schulert lab is the pathogenesis of severe inflammatory disorders of childhood, in particular systemic juvenile idiopathic arthritis (systemic JIA). Although systemic JIA is considered a subtype of JIA, it has distinct clinical and epidemiologic characteristics, notably prominent extra-articular features, including prolonged spiking fevers, rash, lymphadenopathy and serositis.  The pathogenesis of systemic JIA is incompletely understood, but recent work suggests that it fits the paradigm of autoinflammatory disorders.  In contrast to classic autoimmune disorders, which are associated by autoreactive, antigen-specific T cells and autoantibodies, autoinflammatory disorders display abnormal activation of innate immune effector cells, most notably monocytes/macrophages and neutrophils.

Children with systemic JIA are at high risk for life threatening complications, including macrophage activation syndrome (MAS) and chronic lung disease. MAS is a potentially life-threatening episode of overwhelming inflammation occurring in 10-30% of systemic JIA patients, and is characterized by fevers, cytopenias, coagulopathy, liver and central nervous system dysfunction, and a systemic cytokine storm. Chronic lung disease (SJIA-LD) is a recently recognized and poorly understood complication that has emerged as a key driver of systemic JIA morbidity and mortality. The long-term goal of the lab is to determine the course and pathophysiology of severe complications of systemic JIA, leading to targeted therapy that improves patient outcomes.

Publications

Schulert, G; Vastert, SJ; Grom, AA. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.

Grom, AA; Canna, SW; Abu-Arja, RF; Sinha, R; Peixoto, L; Cannizzaro, E; Chandrakasan, S; Driest, K; Marsh, R; Neven, B; et al. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.

Erkens, RG A; Calis, JJ A; Verwoerd, A; De Roock, S; Ter Haar, NM; Den Engelsman, G; Van der Veken, LT; Ernst, RF; Van Deutekom, HW M; Pickering, A; et al. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.

Heshin-Bekenstein, M; Baron, S; Schulert, G; Shusterman, A; Fidel, V; Ben-Shahar, Y; Shukrun, R; Binenbaum, Y; Elhasid, R. Neutrophils extracellular traps formation may serve as a biomarker for disease activity in oligoarticular juvenile idiopathic arthritis: a pilot study. Arthritis Research and Therapy. 2023; 25:135.

Inoue, N; Schulert, GS. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Arthritis Research and Therapy. 2023; 25:48.

Rao, S; Jing, N; Liu, X; Lorman, V; Maltenfort, M; Schuchard, J; Wu, Q; Tong, J; Razzaghi, H; Mejias, A; et al. Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program. Scientific Reports. 2023; 13:21005.

Verweyen, EL; Thakkar, K; Dhakal, S; Baker, E; Chetal, K; Schnell, D; Canna, S; Grom, AA; Salomonis, N; Schulert, GS. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133:e166741.

Woo, JM P; Simmonds, F; Dennos, A; Son, MB F; Lewandowski, LB; Rubinstein, TB; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:2285-2294.

Towe, C; Grom, AA; Schulert, GS. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.

Schulert, GS; Kessel, C. Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America. 2023; 49:895-911.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; et al. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.

Chen, L; Mamutova, A; Kozlova, A; Latysheva, E; Evgeny, F; Latysheva, T; Savostyanov, K; Pushkov, A; Zhanin, I; Raykina, E; et al. Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2. Journal of Allergy and Clinical Immunology. 2023; 152:771-782.

Rai, S; Schulert, GS; Towe, C. New developments related to lung complications in pediatric rheumatic disease. Current Opinion in Rheumatology. 2023; 35:273-277.

Mansfield, LM; Lapidus, SK; Romero, SN; Moorthy, LN; Adler-Shohet, FC; Hollander, M; Cherian, J; Twilt, M; Lionetti, G; Mohan, S; et al. Increase in pediatric recurrent fever evaluations during the first year of the COVID-19 pandemic in North America. Frontiers in Pediatrics. 2023; 11:1240242.

Roberts, JE; Williams, K; Dallas, J; Eckert, M; Huie, L; Smitherman, E; Soulsby, WD; Zhao, Y; Son, MB F; Abel, N; et al. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. The Journal of rheumatology. 2023; 50:1047-1057.

Smitherman, EA; Chahine, RA; Beukelman, T; Lewandowski, LB; Rahman, AK M F; Wenderfer, SE; Curtis, JR; Hersh, AO; Abel, N; Abulaban, K; et al. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75:1553-1562.

De Benedetti, F; Grom, A; Brogan, P; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, G; Quartier, P; et al. OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). 2023; 110-111.

Ruperto, N; Foeldvari, I; Alexeeva, E; Aktay Ayaz, N; Schulert, G; Özen, S; Popov, A; Ramanan, A; Scott, C; Sozeri, B; et al. POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL. 2023; 379.2-37380.

De Benedetti, F; Grom, AA; Brogan, PA; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, GS; Quartier, P; et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.

Kuhn, KA; Stahly, A; Konig, MF; Carandang, K; Herndon, C; Backman, C; Callahan, LF; Schulert, G; Fraenkel, L; Ogdie, A. Impact of the COVID-19 Pandemic on Early Career Investigators in Rheumatology: Recommendations to Address Challenges to Early Research Careers. Arthritis Care and Research. 2023; 75:947-955.

Vega-Fernandez, P; Ting, TV; Mar, DA; Schapiro, AH; Deluna, MD; Saper, VE; Grom, AA; Schulert, GS; Fairchild, RM. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75:983-988.

Jhaveri, R; Webb, R; Razzaghi, H; Schuchard, J; Mejias, A; Bennett, TD; Jone, PN; Thacker, D; Schulert, GS; Rogerson, C; et al. Can Multisystem Inflammatory Syndrome in Children Be Managed in the Outpatient Setting? An EHR-Based Cohort Study From the RECOVER Program. Journal of the Pediatric Infectious Diseases Society. 2023; 12:159-162.

Ringold, S; Dennos, AC; Kimura, Y; Beukelman, T; Shrader, P; Phillips, TA; Kohlheim, M; Schanberg, LE; Yeung, RS M; Horton, DB; et al. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:715-723.

Shiff, NJ; Shrader, P; Correll, CK; Dennos, A; Phillips, T; Beukelman, T; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62:804-814.

Teoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; et al. Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. The Pediatric Infectious Disease Journal. 2023; 42:119-121.

Macaraeg, M; Schulert, GS. Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis. RMD Open. 2023; 9:e002611.

Borgia, RE; Gurka, MJ; Filipp, SL; Elder, M; Cardel, M; Shiff, NJ; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.

Smitherman, EA; Chahine, RA; Bitencourt, N; Rahman, AK M F; Lawson, EF; Chang, JC; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2023; 50:98-106.

Brunner, HI; Foeldvari, I; Alexeeva, E; Ayaz, NA; Calvo Penades, I; Kasapcopur, O; Chasnyk, VG; Hufnagel, M; Zuber, Z; Schulert, G; et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.

Bahakel, H; Murphy, CR; Frenck, RW; Grimley, M; Phillips, C; Schulert, G; Spearman, P; Courter, JD; Paulsen, GC; Danziger-Isakov, LA. 1119. Covid-19 Mab Use in High-Risk Pediatric Patients. Open Forum Infectious Diseases. 2022; 9.

Soulsby, WD; Balmuri, N; Cooley, V; Gerber, LM; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; et al. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2022; 20:18.

Neely, J; Ardalan, K; Huber, A; Kim, S; Abel, N; Abulaban, K; Adams, A; Adams, M; Agbayani, R; Aiello, J; et al. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology Online Journal. 2022; 20:50.

Bahakel, H; Murphy, C; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Haslam, DB; Phillips, CL; Courter, J; Spearman, P; et al. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. The Pediatric Infectious Disease Journal. 2022; 41:985-988.

Hahn, T; Daymont, C; Beukelman, T; Groh, B; Hays, K; Bingham, CA; Scalzi, L; Abel, N; Abulaban, K; Adams, A; et al. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2022; 20:107.

Son, MB F; Berbert, L; Young, C; Dallas, J; Newhams, M; Chen, S; Ardoin, SP; Basiaga, ML; Canny, SP; Crandall, H; et al. Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children. JAMA Network Open. 2022; 5:e2241622.

Schulert, GS. The Big Bad Wolf: Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus. The Journal of rheumatology. 2022; 49:1082-1084.

Rao, S; Jing, N; Liu, X; Lorman, V; Maltenfort, M; Schuchard, J; Wu, Q; Tong, J; Razzaghi, H; Mejias, A; et al. Clinical Subphenotypes of Multisystem Inflammatory Syndrome in Children: An EHR-based cohort study from the RECOVER program. 2022; 3:2022.09.26.22280364.

Chen, G; Deutsch, GH; Schulert, GS; Zheng, H; Jang, SR; Trapnell, B; Lee, PY; Macaubas, C; Ho, K; Schneider, C; et al. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.

Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Kernan, KF; Schulert, GS; Seo, P; et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis and Rheumatology. 2022; 74:e1-e20.

Verweyen, EL; Schulert, GS. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology. 2022; 61:926-935.

Dave, I; Estroff, B; Gergely, T; Rostad, CA; Ponder, LA; McCracken, C; Prahalad, S; Abel, N; Abulaban, K; Adams, A; et al. Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. The Journal of rheumatology. 2021; 48:1856-1862.

Beukelman, T; Lougee, A; Matsouaka, RA; Collier, D; Rumsey, DG; Schenfeld, J; Stryker, S; Twilt, M; Kimura, Y; Abel, N; et al. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2021; 19:131.

Schulert, GS; Blum, SA; Cron, RQ. Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. Current Opinion in Pediatrics. 2021; 33:549-555.

Balmuri, N; Soulsby, WD; Cooley, V; Gerber, L; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; et al. Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2021; 19:122.

Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; et al. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.

Erkens, R; Esteban, Y; Towe, C; Schulert, G; Vastert, S. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheumatic Disease Clinics of North America. 2021; 47:585-606.

Kimura, Y; Schanberg, LE; Tomlinson, GA; Riordan, ME; Dennos, AC; Del Gaizo, V; Murphy, KL; Weiss, PF; Natter, MD; Feldman, BM; et al. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.

Ong, MS; Ringold, S; Kimura, Y; Schanberg, LE; Tomlinson, GA; Natter, MD; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.

Gao, DK; Salomonis, N; Henderlight, M; Woods, C; Thakkar, K; Grom, AA; Thornton, S; Jordan, MB; Wikenheiser-Brokamp, KA; Schulert, GS. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. JCI insight. 2021; 6:e147593.

Walsh, KB; Zimmerman, KD; Zhang, X; Demel, SL; Luo, Y; Langefeld, CD; Wohleb, E; Schulert, G; Woo, D; Adeoye, O. miR-181a Mediates Inflammatory Gene Expression After Intracerebral Hemorrhage: An Integrated Analysis of miRNA-seq and mRNA-seq in a Swine ICH Model. Journal of Molecular Neuroscience. 2021; 71:1802-1814.

Rodriguez-Smith, JJ; Verweyen, EL; Clay, GM; Esteban, YM; de Loizaga, SR; Baker, EJ; Do, T; Dhakal, S; Lang, SM; Grom, AA; et al. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet. Rheumatology. 2021; 3:e574-e584.

Mannion, ML; Xie, F; Horton, DB; Ringold, S; Correll, CK; Dennos, A; Beukelman, T; Abel, N; Abulaban, K; Adams, A; et al. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2021; 48:1322-1329.

Verweyen, EL; Pickering, A; Grom, AA; Schulert, GS. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2021; 73:1334-1340.

Rumsey, DG; Lougee, A; Matsouaka, R; Collier, DH; Schanberg, LE; Schenfeld, J; Shiff, NJ; Stoll, ML; Stryker, S; Weiss, PF; et al. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.

Schulert, GS. The IL-18/IFNγ axis in systemic JIA and MAS-new answers, more questions. Rheumatology. 2021; 60:3045-3047.

Ombrello, MJ; Schulert, GS. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. Translational Research: the journal of laboratory and clinical medicine. 2021; 232:1-12.

Cheung, P; Schaffert, S; Chang, SE; Dvorak, M; Donato, M; Macaubas, C; Foecke, MH; Li, TM; Zhang, L; Coan, JP; et al. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nature Immunology. 2021; 22:711-722.

Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; et al. Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. The Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Ferris, A; Kernan, KF; Schulert, GS; et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis and Rheumatology. 2021; 73:e13-e29.

Murphy, ME; Clay, G; Danziger-Isakov, L; Schulert, G; Paulsen, GC. Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. Current Opinion in Pediatrics. 2021; 33:129-135.

King, CD; Boggero, IA; Schulert, GS; Pickerill, HM; Cole, S. Preliminary evidence for conserved transcriptional response to adversity in adults with temporomandibular disorder. PAIN Reports. 2021; 6:e874.

Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology Online Journal. 2020; 18:7.

Cron, RQ; Schulert, GS; Tattersall, RS. Defining the scourge of COVID-19 hyperinflammatory syndrome. The Lancet. Rheumatology. 2020; 2:e727-e729.

Amarilyo, G; Rothman, D; Manthiram, K; Edwards, KM; Li, SC; Marshall, GS; Yildirim-Toruner, C; Haines, K; Ferguson, PJ; Lionetti, G; et al. Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatment responses from the childhood arthritis and rheumatology research alliance (CARRA) PFAPA work group. Pediatric Rheumatology Online Journal. 2020; 18:31.

Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; et al. A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). Journal of Allergy and Clinical Immunology. 2020; 146:1204-1208.e6.

Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Ferris, A; Kernan, KF; Schulert, GS; et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis and Rheumatology. 2020; 72:1791-1805.

Schulert, GS. The Storm Beneath the Storm: MAS-HLH in Inflammatory Myopathies. The Journal of rheumatology. 2020; 47:1461-1463.

Schulert, GS. Can tocilizumab calm the cytokine storm of COVID-19?. The Lancet. Rheumatology. 2020; 2:e449-e451.

Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; et al. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology Online Journal. 2020; 18:53.

Henderson, LA; Canna, SW; Schulert, GS; Volpi, S; Lee, PY; Kernan, KF; Caricchio, R; Mahmud, S; Hazen, MM; Halyabar, O; et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis and Rheumatology. 2020; 72:1059-1063.

Schulert, GS; Cron, RQ. The genetics of macrophage activation syndrome. Genes and Immunity. 2020; 21:169-181.

de Jesus, AA; Hou, Y; Brooks, S; Malle, L; Biancotto, A; Huang, Y; Calvo, KR; Marrero, B; Moir, S; Oler, AJ; et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. The Journal of Clinical Investigation. 2020; 130:1669-1682.

Verweyen, E; Holzinger, D; Weinhage, T; Hinze, C; Wittkowski, H; Pickkers, P; Albeituni, S; Verbist, K; Nichols, KE; Schulert, G; et al. Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. American Journal of Respiratory and Critical Care Medicine. 2020; 201:526-539.

Ferrara, G; Giani, T; Lieberman, SM; Kremer, C; Hong, S; Indolfi, G; Schulert, G; Cron, RQ; Mannion, ML; Lapidus, S; et al. Alagille Syndrome and Chronic Arthritis: An International Case Series. The Journal of Pediatrics. 2020; 218:228-230.e1.

Abid, Q; Best Rocha, A; Larsen, CP; Schulert, G; Marsh, R; Yasin, S; Patty-Resk, C; Valentini, RP; Adams, M; Baracco, R. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI). American Journal of Kidney Diseases. 2020; 75:287-290.

Yasin, S; Solomon, K; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Schiffrin, E; Sleight, A; Grom, AA; Schulert, GS. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2020; 59:442-445.

Yasin, S; Fall, N; Brown, RA; Henderlight, M; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Grom, AA; Schulert, GS. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2020; 59:361-366.

Lee, PY; Schulert, GS; Canna, SW; Huang, Y; Sundel, J; Li, Y; Hoyt, KJ; Blaustein, RB; Wactor, A; Do, T; et al. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2020; 79:225-231.

Contact Us

A photo of Grant Schulert, MD, PhD.

Grant Schulert, MD, PhD
Assistant Professor, Division of Rheumatology

phone: 513-363-4676
email: grant.schulert@cchmc.org